Olaparib/abiraterone combo approved in European Union for mCRPC
December 21st 2022The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
FDA delays decision on olaparib/abiraterone combo for mCRPC
December 15th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
177Lu-PSMA-617 significantly improves rPFS in earlier mCRPC setting
December 6th 2022According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting.
Renal functional decline after radical nephrectomy strongly associated with age
December 2nd 2022“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Can theranostics improve outcomes in high-risk localized prostate cancer?
December 1st 2022Standard treatment is insufficient for some patients with high-risk localized prostate cancer, and the emerging field of theranostics provides a potential opportunity to improve outcomes, said Karen Elizabeth Hoffman, MD, MHSc, MPH.
Genentech withdraws atezolizumab frontline indication for metastatic urothelial carcinoma
November 29th 2022The confirmatory phase 3 IMvigor130 trial did not show an overall survival advantage with frontline atezolizumab plus chemotherapy vs chemotherapy alone in patients with advanced urothelial carcinoma.
Darolutamide now available in England for mHSPC
November 29th 2022Approval of the treatment was based on the placebo-controlled phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT and docetaxel boosted overall survival versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Novel biomarker emerges for salvage RT approach in biochemically recurrent prostate cancer
November 11th 2022A higher score on PORTOS, an expression signature of 24 DNA damage repair and immune pathway genes, predicted improved response to dose-intensified salvage radiotherapy after radical prostatectomy in patients with biochemically recurrent prostate cancer.